logo-loader
viewANGLE PLC

ANGLE to present results from recent collaboration on circulating tumor cells at Molecular Med Tri-Con 2020 Conference

The collaboration with BioView Ltd. has looked at developing an integrated workflow for identifying clinical biomarkers on circulating tumor cells

Cancer cell
The presentation will take place on March 4 2020 in the Muscone South Convention Centre, San Francisco

ANGLE PLC (LON:AGL) (OTCMKTS:ANPCY), a world leading liquid biopsy company, and BioView Ltd. (TASE:BIOV) will present results of their recent collaboration to develop an integrated workflow for identifying clinical biomarkers on circulating tumor cells (CTCs) at the Molecular Med Tri-Con 2020 Conference in San Francisco (Tri-Con) on March 4.

The presentation, "Combining Cell Harvesting and Imaging Technologies for CTC Liquid Biopsy Sample-to-Answer", will be presented by Anne-Sophie Pailhes-Jimenez, ANGLE Senior R&D Group Leader at Molecular Med Tri-Con 2020.

READ: ANGLE lifted by independent study of its Parsortix system

The collaboration combines ANGLE's Parsortix system, which enables a liquid biopsy (a simple blood test) to be used to provide the cancer cells for analysis in a format suitable for multiple subsequent downstream analyses, and BioView's Duet imaging and analysis system, which provides all essential functions required to transform resource-heavy manual CTC detection and analysis into an automated, high-throughput, high-capacity process that is suited to clinical practice.

Through the collaboration, ANGLE and BioView are integrating their best-in-class technologies to create a workflow for the isolation and characterisation of CTCs with the goal of providing clinical insights to physicians such as the expression of HER-2 (in relation to the drug Herceptin) and PD-L1 (in relation to immunotherapy drugs).

ANGLE founder and chief executive, Andrew Newland, commented: "The combination of two leading-edge technologies, ANGLE's Parsortix CTC enrichment system and BioView's imaging and detection technology, provides a powerful sample-to-answer workflow for the characterisation of CTCs. Such standardised workflows will help support the development of a wide range of clinical applications for CTCs."

The Tri-Con Conference is a leading industry event in the personalised medicine space, and the upcoming event will focus on emerging therapeutic, diagnostic, and technology approaches to advance precision medicine. 

The presentation will take place at 12.25pm on March 4 2020 in the Muscone South Convention Centre, San Francisco.

Quick facts: ANGLE PLC

Price: 63.5 GBX

AIM:AGL
Market: AIM
Market Cap: £109.73 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ANGLE CEO reports 'progress across multiple fronts' and talks big new...

ANGLE PLC's (LON:AGL) (OTCQX:ANPCY) Andrew Newland speaks to Proactive to update on progress since the COVID-19 lockdown began. He says a key focus during the period has been on finalising the significant amount of written documentation and analysis for the firm’s imminent submission to the...

4 weeks, 1 day ago

2 min read